Statutory Rules 1994 No. 2331
__________________
Health Insurance (1994-1995 Pathology Services Table) Regulations
I, The Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, make the following Regulations under the Health Insurance Act 1973.
Dated 27 June 1994.
BILL HAYDEN
Governor-General
By His Excellency’s Command,
CARMEN LAWRENCE
Minister for Human Services and Health
____________
Citation
1. These Regulations may be cited as the Health Insurance (1994-1995 Pathology Services Table) Regulations.
Commencement
2. These Regulations commence on 1 July 1994.
Repeal of Health Insurance (1993-1994 Pathology Services Table) Regulations
3. Statutory Rules 1993 No. 270 are repealed.
Pathology services table
4. The table of pathology services in the Schedule is prescribed for the purposes of subsection 4a (2) of the Health Insurance Act 1973.
___________
SCHEDULE Regulation 4
TABLE OF PATHOLOGY SERVICES
PART 1—RULES OF INTERPRETATION
Interpretation of Table
Rule 1. (1) In this Table:
“patient episode” means:
(a) a pathology service or pathology services (other than a pathology service to which paragraph 1 (1) (b) refers) provided for a single patient whose need for the service or services was determined under subsection 16a (1) of the Act on the same day, whether the services:
(i) are requested by 1 or more practitioners; or
(ii) are described in a single item or in more than 1 item; or
(iii) are rendered by 1 approved pathology practitioner or more than 1 approved pathology practitioner; or
(iv) are rendered on the same day or on different days; or
(b) a pathology service to which rule 4 refers that is provided in the circumstances set out in that rule that relates to the service;
“recognised pathologist” means a medical practitioner recognised as a specialist in pathology by a determination under section 3D or subsection 61 (3) of the Act;
“serial examinations” means a series of examinations requested on 1 occasion whether or not:
(a) the materials are received on different days by the approved pathology practitioner; or
(b) the examinations or cultures were requested on 1 or more request forms by the treating practitioner;
“the Act” means the Health Insurance Act 1973.
1. (2) In these Rules, a reference to a request to an approved pathology practitioner includes a reference to a request for a pathologist-determinable service to which subsection 16a (6) of the Act applies.
1. (3) A reference in this Table by number to an item that is not included in this Table is a reference to the item that has that number in the general medical services table or the diagnostic imaging services table, as the case requires.
1. (4) A reference to a Group in the Table includes every item in that Group.
Precedence of items
2. (1) If a service is described:
(a) in an item in general terms; and
(b) in another item in specific terms;
only the item that describes the service in specific terms applies to the service.
2. (2) Subject to subrule (3), if:
(a) subrule (1) does not apply; and
(b) a service is described in 2 or more items;
only the item that provides the lower or lowest fee for the service applies to the service.
2. (3) If an item is expressed to include a pathology service that is described in another item, the other item does not apply to the service in addition to the first-mentioned item, whether or not the services described in the 2 items are requested separately.
Circumstances in which services rendered following 2 requests to be taken to have been rendered following 1 request
3. (1) In subrule 3 (2), “service” includes assay, estimation and test.
3. (2) Two or more pathology services (other than services to which, under rule 4, this rule does not apply) rendered for a patient following 2 or more requests are taken to have been rendered following a single request if:
(a) the services are listed in the same item; and
(b) the patient’s need for the services was determined under subsection 16a (1) of the Act on the same day even if the services are rendered by an approved pathology practitioner on more than one day.
Services to which rule 3 does not apply
4. (1) Rule 3 does not apply to:
(a) a pathology service specified in item 66201, other than an estimation of fructosamine or lithium; or
(b) quantitative estimation, described in item 66365, of 1 or more fractions of neonatal bilirubin;
if:
(c) the service is rendered in relation to a single specimen taken on each of not more than 4 occasions in a period of 24 hours; and
(d) the service is rendered to a patient in a hospital unit where:
(i) the presence of 1 nurse is required for each group of not more than 4 patients; and
(ii) the condition of the patients is continuously observed in relevant respects; and
(e) in order to render the service, an approved pathology practitioner who is a recognised pathologist has to arrange for a member of the laboratory staff of the approved pathology authority concerned to undertake duties in respect of the service that are in addition to the usual duties of the staff member; and
(f) the account for the service is endorsed “Rule 3 Exemption”.
4. (2) Rule 3 does not apply to any of the following pathology services:
(a) estimation of prothrombin time in respect of a patient undergoing anticoagulant therapy;
(b) quantitative estimation of lithium in respect of a patient undergoing lithium therapy;
(c) a service described in item 65007 in relation to a patient undergoing chemotherapy for neoplastic disease or immunosuppressant therapy;
(d) a service described in item 65007 in relation to methotrexate, gold or penicillamine therapy of a patient;
(e) a service described in item 66201 in relation to methotrexate therapy of a patient;
(f) quantitative estimation of urea, creatinine and electrolytes in relation to:
(i) cis-platinum therapy of a patient; or
(ii) chronic renal failure of a patient being treated in a dialysis program conducted by a recognised hospital;
if:
(g) under a request for a service, no more than 6 tests are requested; and
(h) the tests are performed within 6 months of the request; and
(i) the account for the service is endorsed “Rule 3 Exemption”.
4. (3) Rule 3 does not apply to a pathology service:
(a) to which item 66217 applies; and
(b) for which a specimen is collected on each of 3 days for the purpose of making a valid estimation; and
(c) for which the account is endorsed “Rule 3 Exemption”.
Item taken to refer only to the first service of a particular kind
5. For the purposes of an item in Group P1 (Haematology):
(a) if pathology services of a kind referred to in item 65017 or 65019 are rendered for a patient during a period when the patient is in hospital, the item applies only to the first pathology service of that kind rendered for the patient during that period; and
(b) if:
(i) tests (except tests mentioned in item 65023) are carried out in relation to a patient episode; and
(ii) specimen material from the patient episode is stored; and
(iii) in response to a request made within 14 days of the patient episode, further tests (except tests mentioned in item 65023) are carried out on the stored material;
the later tests and the earlier tests are taken to be part of one patient episode.
Certain items not to apply to a service referred by one pathology practitioner to another
6. (1) In this rule:
“designated pathology service” means a pathology service described in item 66241, 66417 or 69241.
6. (2) Subject to subrule (3), if an approved pathology practitioner in an approved pathology authority:
(a) has been requested to render a pathology service that includes 2 or more tests included in a designated pathology service; and
(b) is able to perform 1 or more, but not all, of the tests because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority in relation to that test or those tests; and
(c) requests an approved pathology practitioner in another approved pathology authority to render 1 or more, but not all, of the tests;
the service rendered by the second-mentioned practitioner is taken to be the designated pathology service.
6. (3) Items in Group P10 (Patient episode initiation) do not apply to the second-mentioned approved pathology practitioner in subrule (2).
Certain tests on stored material to be treated as part of the same patient episode
7. For the purposes of items in Group P2 (Chemical):
(a) if a pathology service that involves the measurement of a substance in urine requires calculation of a substance/creatinine ratio, the service is taken to include the measurement of creatinine necessary for the calculation; and
(b) if:
(i) tests are carried out in relation to a patient episode; and
(ii) specimen material from the patient episode is stored; and
(iii) in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;
the later tests and the earlier tests are taken to be part of one patient episode.
Meaning of “serial examinations or cultures”
8. For the purposes of an item in Group P3 (Microbiology):
(a) “serial examinations or cultures” means a series of examinations or cultures requested on 1 occasion whether or not:
(i) the materials are received on different days by the approved pathology practitioner; or
(ii) the examinations or cultures were requested on 1 or more request forms by the treating practitioner; and
(b) if:
(i) tests are carried out in relation to a patient episode; and
(ii) specimen material from the patient episode is stored; and
(iii) in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;
the later tests and the earlier tests are taken to be part of one patient episode.
Tests in Group P4 (Immunology) relating to antibodies
9. For the purposes of items in Group P4 (Immunology), in items 71119, 71121, 71123 and 71125, if:
(a) tests are carried out in relation to a patient episode; and
(b) specimen material from the patient episode is stored; and
(c) in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;
the later tests and the earlier tests are taken to be part of one patient episode.
Tests on biopsy material—Group P5 (Tissue Pathology) and Group P6 (Cytology)
10. (1) For the purposes of items in Group P5 (Tissue Pathology):
(a) “biopsy material” means all tissue (other than a bone marrow biopsy) received by an approved pathology practitioner from an operation, or a group of operations, performed on a patient at the same time; and
(b) if:
(i) a pathology service that comprises the examination of biopsy material is rendered under any of those items; and
(ii) a further pathology service mentioned in any of those items is also rendered using that biopsy material;
those pathology services are taken to be 1 pathology service; and
(c) “cytology” means microscopic examination of 1 or more stained preparations of cells separated naturally or artificially from their normal environment by methods recognised as adequate to demonstrate their structure to a degree sufficient to enable an opinion to be formed about whether they are likely to be normal, abnormal but benign, or abnormal and malignant. In accordance with customary laboratory practice examination of a blood film and a bone marrow aspirate is excluded from this definition.
10. (2) For the purposes of Groups P5 and P6 of the Pathology Services Table, services in Group P6 include any services described in Group P5 on the material submitted for a test in Group P6.
10. (3) For the purposes of subrule 10. (2)—any sample submitted for cytology from which a cell block is prepared does not qualify for a Group P5 item.
Items in Groups P10 (Patient episode initiation) and P11 (Specimen referred) not to apply in certain circumstances
11. (1) For the purposes of this rule and items in Groups P10 (Patient episode initiation) and P11 (Specimen referred):
“institution” means a place at which residential accommodation or day care is, or both residential accommodation and day care are, made available to:
(a) disadvantaged children; or
(b) juvenile offenders; or
(c) aged persons; or
(d) chronically ill psychiatric patients; or
(e) homeless persons; or
(f) unemployed persons; or
(g) persons suffering from alcoholism; or
(h) persons addicted to drugs; or
(i) physically or mentally handicapped persons;
but does not include:
(j) a hospital; or
(k) a nursing home; or
(l) accommodation for aged persons that is attached to a nursing home or situated within a nursing home complex;
“licensed collection centre” has the same meaning as in Part IIa of the Act;
“prescribed laboratory” means a laboratory operated by:
(a) the Commonwealth; or
(b) a State or internal Territory; or
(c) an authority of a State or internal Territory; or
(d) an Australian tertiary education institution;
“specimen collection centre” has the same meaning as in Part IIa of the Act;
“treating practitioner” has the same meaning as in paragraph 16a (1) (a) of the Act.
11. (2) If a service described in an item in Group P10 or P11 is rendered by, or on behalf of, an approved pathology practitioner who is a recognised pathologist, the relevant one of those items does not apply to the service if:
(a) the service is rendered upon a request made in the course of an out-patient service at a recognised hospital; or
(b) the service is rendered upon a request made for a patient who is a private patient in a recognised hospital when the request is made; or
(c) the pathology equipment of a recognised hospital, or a prescribed laboratory, is used rendering the service; or
(d) a member of the staff of a recognised hospital, or a prescribed laboratory, participates in the service in the course of the member’s employment with the hospital or laboratory.
11. (3) An item in Group P10 or P11 does not apply to a pathology service to which subsection 16a (7) of the Act applies.
11. (4) An item in Group P10 or P11 does not apply to a pathology service unless at least one item in Groups P1 to P9 also applies to that service.
11. (5) Subject to subrule (7), if one item in Group P10 applies to a patient episode, no other item in that Group applies to that patient episode.
11. (6) An item in Group P11 applies only to the approved pathology practitioner or approved pathology authority to whom the specimen mentioned in the item was referred.
11. (7) If, in respect of the same patient episode:
(a) services referred to in 1 or more items in Group P5 and one or more of Groups P1, P2, P3, P4, P6, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority; and
(b) services referred to in 1 or more items in Group P6 and one or more of Groups P1, P2, P3, P4, P5, P7 and P8 are rendered by another approved pathology practitioner in another approved pathology authority;
the fee specified in the applicable item in Group P10 is payable to both approved pathology practitioners.
11. (8) If more than one specimen is collected from a person on the same day for the provision of pathology services:
(a) in accordance with more than one request; and
(b) in or by a single approved pathology authority;
only a single amount specified in the applicable item in Group P10 is payable for the services.
Application of an item in Group P11 (Specimen referred) to a service excludes certain other items
12. If item 73921 applies to a patient episode, none of the items in Group P10 applies to any pathology service rendered by the approved pathology authority or approved pathology provider who claimed item 73921 in respect of that patient episode.
Circumstances in which an item in Group P11 (Specimen referred) does not apply
13. (1) An item in Group P11 does not apply to a referral if:
(a) a service in respect of the same patient episode has been carried out by the referring approved pathology authority; and
(b) the approved pathology authority to which the referral is made is related to the referring approved pathology authority.
13. (2) An approved pathology authority is related to another approved pathology authority for the purposes of subclause (1) if:
(a) both approved pathology authorities are employed (including employed under contract) by the same person, whether or not that person is also an approved pathology authority; or
(b) either of the approved pathology authorities is employed (including employed under contract) by the other; or
(c) if both of the approved pathology authorities are corporations—the approved pathology authorities are related corporations within the meaning of the Corporations Law; or
(d) the approved pathology authorities are partners (whether or not either or both of the approved pathology authorities are individuals and whether or not other persons are in partnership with either or both of the approved pathology authorities).
Abbreviations
14. (1) The abbreviations in Part 3 of this Table may be used to identify particular pathology services or groups of pathology services.
14. (2) The names of services not listed in Part 3 of this Table must be written in full.
PART 2—SERVICES AND FEES
GROUP P1—HAEMATOLOGY
Item number
Pathology service
Fee
$
65001
Erythrocyte count, C-reactive protein, erythrocyte sedimentation rate, blood viscosity, haematocrit, haemoglobin, platelet count, leucocyte count, or reticulocyte count—1 or 2 tests
5.60
65003
3 or more tests described in item 65001, and calculation or measurement of cell index or indices
7.65
65005
Examination of blood film, or 5 part differential cell count, or both 5 part differential cell count and examination of blood film, including (if performed):
(a) a service described in item 65027; and
(b) any of the following services:
(i) examination of blood film by special stains to demonstrate Heinz bodies, parasites or iron;
(ii) examination of a blood film with alpha-naphthyl acetate esterase, chloroacetate esterase, neutrophil alkaline phosphatase, nitroblue tetrazolium, periodic acid Schiff or Sudan Black stains;
(iii) Kleihauer test for HbF on blood film
10.10
65007
Full blood examination (consisting of the services described in items 65003 and 65005)
17.50
65009
Haemolysis or metabolic enzymes—assessment by:
(a) erythrocyte autohaemolysis test;
(b) erythrocyte fragility test;
(c) sugar water test;
(d) erythrocyte metabolic enzyme test;
(e) heat denaturation test;
(f) isopropanol precipitation test;
(g) acid haemolysis test; and
(h) quantitation of muramidase in serum or urine;
1 or more tests
23.30
65011
Haemoglobinopathy, tests for the diagnosis of, consisting of haemoglobin electrophoresis and 2 of:
(a) examination for HbH; or
(b) quantitation of HbA2; or
(c) quantitation of HbF;
including a service described in item 65001, 65003, 65005 or 65007 (if performed)
36.30
65013
Bone marrow trephine biopsy—histopathological examination of sections of bone marrow, including (if performed):
(a) examination of aspirated material; and
(b) special stains or immunochemical techniques (if any); and
(c) a service described in item 65001, 65003, 65005, 65007 or 65015
111.50
65015
Bone marrow—examination of aspirated material (including clot sections where necessary), including (if performed):
(a) special stains or immunochemical techniques (if any); and
(b) a service described in item 65001, 65003, 65005 or 65007
80.95
65017
Blood grouping (including back-grouping if performed)—ABO and Rh (D antigen)
9.80
65019
Blood grouping—Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system—1 or more systems, including a service described in item 65017 (if performed)
19.50
65021
Blood grouping (including back-grouping if performed), and examination of serum for Rh and other blood group antibodies, including:
(a) identification and quantitation of any antibodies detected; and
(b) (if performed) a service described in item 65001, 65003, 65005 or 65007
36.30
65023
Compatibility tests—all tests performed on any 1 day, including:
(a) all grouping checks of patient and donor; and
(b) examination for antibodies, and, if necessary, quantitation of any antibodies detected; and
(c) a service described in item 65001, 65003, 65005, 65007, 65017 or 65021 (if performed)
88.60
65025
Examination of serum for blood group antibodies (including identification and, if necessary, quantitation of any antibodies detected)
16.05
65027
1 or more of the following tests:
(a) direct Coombs test;
(b) qualitative or quantitative test for cold agglutinins or heterophile antibodies;
(c) qualitative spectroscopic examination of blood for abnormal haemoglobins;
(d) qualitative test for red cell porphyrins and detection of metalbumin (Schumm’s test)
8.85
65029
Skin bleeding time, coagulation time, prothrombin time, activated partial thromboplastin time, thrombin time (including test for presence of an inhibitor and serial tests for fibrinolysis), test for factor XIII deficiency, fibrinogen, or 1 of: fibrinogen degradation products, fibrin monomer or D-dimer—1 test
12.25
65031
2 tests described in item 65029
16.20
65033
3 tests described in item 65029
20.15
65035
4 or more tests described in item 65029
24.10
65037
Quantitation, by 1 or more techniques, of: plasminogen, antithrombin III, Protein C, Protein S, heparin cofactor II and euglobulin clot lysis time and test for lupus anticoagulant—1 to 3 tests
24.05
65039
4 or more tests described in item 65037
76.40
65041
Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or similar substance—1 or more tests
48.10
65043
Heparin quantitation when monitoring a patient on subcutaneous heparin or low molecular weight heparin—1 or more tests
32.10
65045
Quantitation of Von Willebrand’s factor antigen (factor VIII related antigen), Von Willebrand’s factor (ristocetin cofactor), factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, or Passovy factor—1 test
32.05
65047
2 tests described in item 65045
46.20
95049
3 or more tests described in item 65045
60.35
GROUP P2—CHEMICAL
66201
Quantitation in serum, plasma, urine or other body fluid, by any method except reagent strip (with or without reflectance meter or electrophoresis) of: alanine aminotransferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total and any fractions), calcium (total, dialysed or ionised), chloride, creatine kinase, creatine kinase isoenzymes (if not performed as described in item 66249), creatinine, fructosamine, gamma glutamyl transpeptidase, globulin, glucose, lactate dehydrogenase, lipase, lithium, magnesium, phosphate, potassium, total protein, sodium, urate or urea—1 test
9.90
66203
2 tests described in item 66201
11.95
66205
3 tests described in item 66201
14.00
66207
4 tests described in item 66201
16.05
66209
5 tests described in item 66201
18.10
66211
6 or more tests described in item 66201
20.15
66213
Test by any method (except reagent strip or dip-stick):
(a) for the presence of:
(i) the following urine constituents—bilirubin, cystine (cysteine), haemoglobin, melanin (melanogen), myoglobin, porphobilinogen, porphyrins, urobilinogen; or
(ii) cryoglobulins or cryofibrinogen in plasma; or
(b) of pH of body fluids other than urine (not including urine acidification test);
1 or more tests
9.60
66215
Quantitation of cryoglobulins or cryofibrinogen following their detection in a test described in item 66213, including that service—1 or more tests
14.50
66217
Tests by any chemical method (except reagent strip or dip-stick) for the following faecal constituents—haemoglobin, porphyrins, reducing substances—each test, to a maximum of 3 tests taken on separate days
6.40
66219
Identification of human haemoglobin in faeces, including a service (if performed) described in item 66217—1 test in a 28 day period
12.20
66223
Osmolality, estimation by osmometer, in serum or in urine—1 or more tests
24.05
66225
Quantitation of:
(a) blood gases (including pO2, oxygen saturation and pCO2); and
(b) bicarbonate and pH;
including any other measurement (e.g., haemoglobin or potassium) or calculation performed on the same specimen—1 or more tests on 1 specimen
32.85
66227
Quantitation of blood gases, bicarbonate and pH as described in item 66225 on each specimen in excess of 1 to a maximum of 6 specimens within any 1 day
8.70
66229
Calculus, analysis of 1 or more
29.80
66231
All qualitative and quantitative tests on blood, urine or other body fluid for:
(a) a drug or drugs of abuse (including illegal drugs and legally available drugs taken other than in appropriate dosage); or
(b) ingested or absorbed toxic chemicals;
including a service described in item 66235, 66237 or 66239 (if performed), but excluding:
(c) the surveillance of sports people and athletes for performance improving substances; and
(d) the monitoring of patients participating in a drug abuse treatment program
40.50
66235
Quantitation, not elsewhere described in this Table by any method or methods, in blood or other body fluid, of a drug being used therapeutically by the patient from whom the specimen was taken—1 test
20.20
66237
2 tests described in item 66235
28.30
66239
3 or more tests described in item 66235
36.40
66241
Tests described in any of items 66235 to 66237 (inclusive), if the number of tests relating to the same patient episode does not exceed 3—each test to a maximum of 2 tests
(Item is subject to rule 6)
8.10
66243
Amniotic fluid, spectrophotometric examination of, and quantitation of:
(a) lecithin/sphingomyelin ratio; or
(b) palmitic acid, phosphatidylglycerol or lamellar body phospholipid;
1 or more tests
32.10
66247
Electrophoresis
(including quantitation), of serum and either or both urine or other body fluid all collected within a 28 day period, to demonstrate protein classes or presence of paraprotein, including the preliminary quantitation of:
(a) total protein, albumin and globulin; or
(b) total relevant enzyme activity;
2 or more tests
44.30
66249
Electrophoresis, quantitative or qualitative, of serum, urine or other body fluid to demonstrate:
(a) protein classes; or
(b) presence and amount of paraprotein; or
(c) the isoenzymes of lactate dehydrogenase, alkaline phosphatase and creatine kinase;
including the preliminary quantitation of total protein, albumin and globulin or of total relevant enzyme activity
29.80
66250
Electrophoresis, quantitation or qualitative, of serum, for demonstration of lipoprotein subclasses, if the cholesterol is >6.5 mmol/l and triglyceride >3.0 mmol/l or in the diagnosis of types III and IV hyperlipidaemia—each episode to a maximum of 2 episodes in a 12 month period
29.80
66255
Alpha-1-acid glycoprotein, alpha-1-antitrypsin, or alpha-2-macroglobulin—quantitation in serum, urine or other body fluid—1 or more tests
19.65
66257
C-1 esterase inhibitor—quantitation
19.65
66258
C-1 esterase inhibitor—functional assay
43.95
66261
CA-125 antigen, CA-15.3 antigen, CA-19.9 antigen, carcinoembryonic antigen (CEA), mammary serum antigen, mucin-like carcinoma-associated antigen (1 or more fractions), neuron-specific enolase, or thyroglobulin in serum or other body fluid, in the monitoring or confirmation of malignancy—quantitation—1 test
19.65
66262
2 or more tests described in item 66261
36.20
66263
Iron studies, consisting of quantitation of:
(a) serum iron;
(b) transferrin or iron binding capacity; and
(c) ferritin
38.20
66265
Serum B12 or serum folate—1 or more tests within a 28-day period
24.05
66267
Red cell folate and serum B12, and, if required, serum folate, to a maximum of 3 episodes in a 12-month period
43.90
66269
Vitamins—quantitation of vitamins A, B1, B2, B3, B6, C, and E in blood, urine or other body fluid—1 or more tests within a 6-month period
29.80
66271
Vitamin D or D fractions—1 or more tests
29.80
66277
Quantitation of aluminium (except if item 66325 applies), arsenic, beryllium, cadmium, copper, chromium, gold, manganese, mercury, nickel, selenium, or strontium, in blood, urine or other body fluid or tissue—1 or more tests in a 6-month period
34.90
66279
Blood lead quantitation (other than for occupational health screening purposes) to a maximum of 3 tests in a 6–month period—each test
29.80
66281
Porphyrins (1 or more fractions), catecholamines (1 or more fractions), hydroxymethoxymandelic acid (HMMA), homovanillic acid (HVA), metanephrines, methoxyhydroxyphenylethylene glycol (MHPG), or phenylacetic acid (PAA)—quantitation—1 or more tests
38.95
66283
Quantitation of:
(a) faecal fat; or
(b) breath hydrogen in response to loading with disaccharides;
1 or more tests within a 28-day period
38.95
66285
Enzymes—quantitation of 1 or 2 in solid tissue or tissues other than blood elements
38.95
66287
Quantitation of 3 to 5 enzymes as described in item 66285
72.55
66289
Quantitation of 6 or more enzymes as described in item 66285
96.25
66291
Thyroid function tests, including thyrotrophin (TSH) and 1 or more of the following tests—free thyroxine index, free thyroxine, free T3, total T3, thyroxine-binding globulin
40.50
66293
Thyrotrophin releasing hormone (TRH) test, including provision and administration of TRH and quantitation of hormones
48.10
66295
Personal performance by a recognised pathologist of 1 or more of the following:
(a) growth hormone suppression by glucose loading;
(b) growth hormone stimulation by exercise;
(c) dexamethasone suppression test;
(d) L-dopa stimulation of growth hormone
11.45
66297
Personal performance by a recognised pathologist of 1 of the following:
(a) gonadotrophin releasing hormone stimulation test;
(b) synacthen stimulation test;
(c) glucagon stimulation test with C-peptide measurement;
(d) pentagastrin stimulation of thyrocalcitonin release;
(e) secretin stimulation of gastrin release;
(f) insulin hypoglycaemia;
(g) arginine infusion
38.20
66299
Personal performance by a recognised pathologist of 2 or more tests described in item 66297
61.10
66315
Quantitation of hormone receptors on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast—1 or more tests
77.90
66317
Quantitation of HDL cholesterol or apolipoprotein B/A1 ratio in a patient who:
(a) has a serum cholesterol level >5.5 mmol/1; or
(b) is on prescribed lipid lowering drugs; or
(c) has a fasting serum triglyceride level >2.0 mmol/1;
each episode to a maximum of 4 episodes in a 12-month period
12.20
66319
Quantitation of glycosylated haemoglobin performed in the management of established diabetes—each test to a maximum of 4 tests in a 12-month period
16.40
66321
Quantitation, in the 2nd trimester of pregnancy, of alpha fetoprotein, human chorionic gonadotrophin, oestriol and any other substance to detect foetal abnormality, including a service described in 1 or more of items 66353, 66373, 73527 and 73529 (if performed)—1 patient episode in a pregnancy
53.80
66323
Test for tryptic activity in faeces in the investigation of diarrhoea of longer than 4 weeks duration in children under 6 years old
10.85
66325
Quantitation of serum aluminium in a patient in a renal dialysis program—each test
34.90
66331
Quantitation (except by reagent strip with or without reflectance meter or electrophoresis) of cholesterol or triglycerides or both in serum, plasma, urine or other body fluid
11.75
66335
A service described in item 66331 and 1 test described in item 66201
14.00
66337
A service described in item 66331 and 2 tests described in item 66201
16.05
66339
A service described in item 66331 and 3 tests described in item 66201
18.10
66341
A service described in item 66331 and 4 or more tests described in item 66201
20.15
66343
Detection or quantitation or both (not including the detection of nicotine and metabolites in smoking withdrawal programs) of a drug, or drugs, of abuse or a therapeutic drug, on a sample collected from a patient:
(a) participating in a drug abuse treatment program; or
(b) being treated for drug effects;
including all tests on blood, urine or other body fluid—each episode, to a maximum of 21 episodes in a 12-month period
20.25
66353
Quantitation in serum or other body fluids of alpha fetoprotein, except if requested as part of item 66321
19.65
66355
Ferritin—quantitation, except if requested as part of iron studies
19.65
66357
Prostate specific antigen or prostatic acid phosphatase—quantitation in the confirmation or monitoring of malignancy—1 test
19.65
66359
2 tests described in item 66357
36.20
66361
Beta-2-microglobulin, caeruloplasmin, haptoglobins, microalbumin in proven diabetes mellitus, or prealbumin—quantitation in serum, urine or other body fluids—1 test
19.65
66363
2 or more tests described in item 66361
36.20
66365
Neonatal bilirubin (1 or more fractions)—quantitation
24.05
66367
Quantitation of acetoacetate, alcohol, amino acids, ammonia, angiotensin converting enzyme, beta-hydroxybutyrate, cholinesterase, cysteine, total free fatty acids, histamine, hydroxyindoleacetic acid, hydroxyproline, lactate, oxalate, pyruvate, serotonin, xylose, or zinc—1 test
24.05
66369
2 or more tests described in item 66367
37.80
66371
TSH—quantitation, except if requested as part of thyroid function test or in association with other hormones or hormone binding proteins described in item 66405
31.15
66373
Human placental lactogen or oestriol—quantitation, except if requested as part of item 66321—1 test
31.15
66375
2 tests described in item 66373
42.05
66405
Quantitation of hormones and hormone binding proteins—ACTH, aldosterone, androstenedione, C-peptide, calcitonin, cortisol, cyclic AMP, DHEAS, 11-deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, hydroxyprogesterone, insulin, LH, oestradiol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(lgF1), free or total testosterone, TSH (where not requested on its own or as part of a thyroid function test), urine steroid fraction or fractions, vasoactive intestinal peptide, vasopressin (antidiuretic hormone)—1 test
31.15
66407
2 tests described in item 66405
42.05
66409
3 tests described in item 66405
52.95
66411
4 tests described in item 66405
63.85
66413
5 tests described in item 66405
74.75
66415
6 or more tests described in item 66405
85.65
66417
Tests described in any of items 66405 to 66413 (inclusive), if the number of tests relating to the same patient episode does not exceed 6—each test to a maximum of 5 tests
(Item is subject to rule 6)
10.90
GROUP P3—MICROBIOLOGY
69201
Microscopy of wet film material other than blood, from 1 or more sites, obtained directly from a patient (not cultures) including:
(a) differential cell count (if performed); or
(b) examination for dermatophytes; or
(c) dark ground illumination; or
(d) stained preparation or preparations, using any relevant stain or stains;
1 or more tests
7.25
69203
Microscopy of faeces for parasites using concentration techniques (including the use of appropriate stains) to a maximum of 3 tests taken on separate days, including a service (if performed) described in item 69201—each test
12.20
69205
Culture and (if performed) microscopy to detect pathogenic micro-organisms (including fungi but excluding viruses), from nasal swabs, throat swabs, eye swabs and ear swabs, including (if performed):
(a) pathogen identification and antibiotic susceptibility testing; or
(b) the detection of antigens not elsewhere described in this Table; or
(c) a service described in item 69201;
specimens from 1 or more sites
19.10
69207
Microscopy and culture to detect pathogenic micro-organisms, including fungi but excluding viruses, from:
(a) skin or other superficial sites, urethra, vagina, cervix or rectum (except for faecal pathogens); or
(b) specimens of sputum (except when part of item 69213);
including (if performed):
(c) the detection of antigens not elsewhere specified in this Table; or
(d) pathogenic identification and antibiotic susceptibility testing; or
(e) a service described in items 69201, 69205 and 73810;
1 or more tests on 1 or more specimens
27.90
69209
Microscopy and culture of postoperative wounds, aspirates of body cavities, synovial fluid, CSF or operative or biopsy specimens, for the presence of pathogenic micro-organisms (including fungi but excluding viruses) involving aerobic and anaerobic culture and the use of different culture media, and including (if performed):
(a) pathogen identification and antibiotic susceptibility testing;
(b) the detection of antigens not elsewhere specified in this Table; or
(c) a service described in item 69201, 69205 or 69207;
specimens from 1 or more sites
37.80
69211
Culture of faeces for faecal pathogens, involving the use of at least 2 selective or enrichment media and culture in at least 2 different atmospheres and including (if performed):
(a) pathogen identification and antibiotic susceptibility testing;
(b) the detection of clostridial toxins or antigens not elsewhere specified in this Table; or
(c) a service described in item 69201;
to a maximum of 3 specimens in any 7-day period—each test
45.85
69213
Microscopy with appropriate stains and culture of 3 specimens of sputum, urine or other body fluids for mycobacteria including (if performed):
(a) microscopy and culture of other bacterial pathogens; or
(b) pathogen identification and antibiotic susceptibility testing; and
(c) a service described in item 69201
64.15
69215
Blood culture for pathogenic micro-organisms (other than viruses), including sub-cultures and (if performed):
(a) identification of any cultured pathogen; and
(b) necessary antibiotic susceptibility testing;
each set of cultures to a maximum of 3 sets
16.80
69217
Urine examination (including serial examination) by any means other than simple culture by dip slide, including:
(a) cell count; and
(b) culture; and
(c) colony count (if performed); and
(d) stained preparations; and
(e) identification of cultured pathogens; and
(f) antibiotic susceptibility testing; and
(g) any examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts
20.30
69219
Detection of:
(a) the antigens of Haemophilus influenzae, Streptococcus pneumoniae, Neisseria, meningitidis, Group B streptococcus respiratory syncytial virus, cryptococcal antigens or Varicella zoster; or
(b) Clostridium difficile toxin (except if the service described in item 69211 has been performed);
1 or more tests
16.05
69221
Detection of Chlamydia from material obtained directly from a patient (not cultures)—1 or more tests
9.60
69223
Detection of herpes simplex virus from material obtained directly from a patient (not cultures)—1 or more tests
9.60
69229
Quantitation of 1 antibody to microbial or exogenous antigens not elsewhere described in the Schedule
13.75
69231
2 tests described in item 69229
21.05
69233
3 tests described in item 69229
28.35
69235
4 tests described in item 69229
35.65
69237
5 tests described in item 69229
42.95
69239
6 or more tests described in item 69229
50.25
69241
Tests described in any of items 69229 to 69237, if the number of tests relating to the same patient episode does not exceed 6—each test to a maximum of 5 tests
(Item is subject to rule 6)
7.30
69243
Hepatitis B surface antigen test
13.60
69245
Hepatitis B serology to define the immune status of an individual, including at least hepatitis B surface antibody or hepatitis B core antibody test, and including a service described in item 69243, 69247 or 69249 (if performed)
18.35
69247
Serological tests to identify the agent causing acute hepatitis (must include hepatitis B surface antigen, hepatitis B core antibody and hepatitis A IgM antibody test and the services described in items 69243, 69245 and 69249)
36.30
69249
Tests performed in the follow-up of a patient with proven hepatitis B, including:
(a) hepatitis B surface antigen test; and
(b) either:
(i) hepatitis Be antigen test; or
(ii) hepatitis B surface antibody test, and
(c) (if performed) services described in items 69243 and 69245
26.35
69251
Antibiotics or antimicrobial chemotherapeutic agents in serum, urine or other body fluid—quantitation—1 or more tests
24.05
69253
Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including:
(a) the determination of 1 of the following: rubella immune status, specific syphilis serology, hepatitis B surface antigen; and
(b) a service described in 1 or more of items 69229, 69243 and 69245 (if performed)
13.75
69255
Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including:
(a) the determination of 2 of the following: rubella immune status, specific syphilis serology or hepatitis B surface antigen;
(b) a service described in 1 or more of items 69229, 69243 and 69245 (if performed)
21.00
69257
Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including:
(a) the determination of all 3 of the following: rubella immune status, specific syphilis serology and hepatitis B surface antigen); and
(b) a service described in 1 or more of items 69229, 69243 and 69245 (if performed)
27.90
69261
Examination for chlamydia (by culture or by the demonstration of chlamydial nucleic acid using a DNA probe) in material obtained directly from a patient, including a service described in item 69221, 69223 or 69263 (if performed)
17.80
69263
Examination for herpes simplex virus of one or more types by culture in material obtained directly from a patient, including a service described in item 69221, 69223 or 69261 (if performed)
27.80
69265
Hepatitis C antibody test
13.75
GROUP P4—IMMUNOLOGY
71061
Immunoelectrophoresis or immunofixation, of serum, urine or other body fluid, and characterisation of, a paraprotein or cryoglobulin not previously characterised, including a service described in 1 or both of items 66213 and 66215 (if performed)—1 or more tests
28.45
71063
Immunoelectrophoresis or immunofixation of serum and urine concurrently collected, and characterisation of, a paraprotein not previously characterised—2 or more tests
42.90
71065
Examination of CSF and serum concurrently collected for the presence of oligoclonal proteins—2 or more tests
42.90
71067
Quantitation of total immunoglobulins A, G, M or D by any method in serum, urine or other body fluid—1 test
14.65
71069
2 tests described in item 71067
23.15
71071
3 or more tests described in item 71067
31.65
71073
Quantitation of all 4 immunoglobulin G subclasses, with a maximum of 2 patient episodes in a 12-month period—each patient episode
103.45
71075
Quantitation of immunoglobulin E (total), with a maximum of 2 patient episodes in a 12-month period—each patient episode
26.35
71077
Quantitation of immunoglobulin E (total) in the follow-up of a patient with proven immunoglobulin-E-secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis, with a maximum of 6 patient episodes in a 12-month period—each patient episode
26.35
71079
Detection of specific immunoglobulin G or E antibodies to single or multiple potential allergens, with a maximum of 4 patient episodes in a 12 month period—each patient episode
23.80
71081
Quantitation of total haemolytic complement
19.65
71083
Quantitation of complement components C3 and C4 or properdin factor B—1 test
19.65
71085
2 tests described in item 71083
28.20
71087
3 or more tests described in item 71083
36.80
71089
Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this Schedule—1 test
28.40
71091
2 tests described in item 71089
51.45
71093
3 or more tests described in item 71089
74.50
71097
Antinuclear antibodies—detection in serum or other body fluids, including quantitation if required
24.80
71099
Double-stranded DNA antibodies—quantitation by 1 or more methods other than the Crithidia method
25.85
71101
Antibodies to 1 or more extractable nuclear antigens—detection in serum or other body fluids
16.95
71103
Characterisation of an antibody detected in a service described in item 71101 (including that service)
50.70
71106
Rheumatoid factor—detection by any technique in serum or other body fluids, including quantitation if required
11.00
71109
Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, cardiolipin, glomerular basement membrane, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, neutrophil cytoplasm, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor)—detection, including quantitation if required, of 1 antibody
33.65
71113
Detection of 2 antibodies described in item 71109
46.20
71115
Detection of 3 antibodies described in item 71109
58.75
71117
Detection of 4 antibodies described in item 71109
71.30
71119
Antibodies to tissue antigens not elsewhere specified in this Table—detection, including quantitation if required, of 1 antibody
16.90
71121
Detection of 2 antibodies specified in item 71119
20.25
71123
Detection of 3 antibodies specified in item 71119
23.60
71125
Detection of 4 or more antibodies specified in item 71119
26.95
71127
Functional tests for lymphocytes—quantitation other than by microscopy of:
(a) proliferation induced by 1 or more mitogens; or
(b) proliferation induced by 1 or more antigens; or
(c) estimation of 1 or more mixed lymphocyte reactions;
including a test described in item 65005 (if performed), with a maximum of 2 patient episodes in a 12-month period—each patient episode
171.85
71129
2 tests described in item 71127
212.30
71131
3 or more tests described in item 71127
252.75
71135
Quantitation of neutrophil function, comprising at least 2 of the following:
(a) chemotaxis;
(b) phagocytosis;
(c) oxidative metabolism;
(d) bactericidal activity;
including any test described in item 65005 (other than nitroblue tetrazolium reduction slide test), with a maximum of 2 patient episodes in a 12-month period—each patient episode
202.70
71137
Quantitation of cell-mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7 antigens, with a maximum of 2 patient episodes in a 12-month period—each patient episode
29.50
71139
Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count by any method, on 1 or more specimens of blood, CSF or serous fluid
101.35
71141
Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more disaggregated tissue specimens
192.35
71143
Characterisation (but not monitoring) of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations in an immunological or haematological malignancy, including a service described in 1 or both of items 71139 and 71141 (if performed) , on a specimen of blood, CSF, serous fluid or disaggregated tissue
253.40
71145
Characterisation (but not monitoring) of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations in an immunological or haematological malignancy, including a service described in 1 or more of items 71139, 71141 and 71143 (if performed), on 2 or more specimens of disaggregated tissues or 1 specimen of disaggregated tissue and 1 or more specimens of blood, CSF or serous fluid
413.70
71147
HLA-B27 typing
31.60
71149
Complete tissue typing for 4 HLA-A and HLA-B Class I antigens (including any separation of leucocytes), including a service described in item 71147 (if performed)
105.50
71151
Tissue typing for HLA-DR, HLA-DP and HLA-DQ Class II antigens (including any separation of leucocytes)—phenotyping or genotyping of 2 or more antigens
115.85
GROUP P5—TISSUE PATHOLOGY
72801
Examination of biopsy material (gross and microscopic) including all tissue processing, staining, and except as provided for in 72805 and 72807—all professional opinions
78.05
72803
Intraoperative frozen section diagnosis of biopsy material, including any other tissue pathology service in Group P5
126.80
72805
Immunohistochemical staining of biopsy material by 1 or more labelled antibody techniques (including immunofluorescence and immunoperoxidase) and including any other tissue pathology service in Group P5
96.25
72807
Electron microscopy of biopsy material including any other tissue pathology service in Group P5
102.35
GROUP P6—CYTOLOGY
73043
Cytology (including serial examinations) of nipple discharge or smears from skin, lip, mouth, nose or anus for detection of precancerous or cancerous changes—1 or more tests
14.80
73045
Cytology (including serial examinations) for malignancy (other than an examination mentioned in item 73053); and including any Group P5 service, if performed on:
(a) specimens resulting from washings or brushings from sites not specified in item 73043; or
(b) a single specimen of sputum or urine; or
(c) 1 or more specimens of other body fluids;
1 or more tests
29.00
73047
Cytology of a series of 3 sputum or urine specimens for malignant cells
60.35
73049
Cytology material obtained directly from a patient by fine needle aspiration of solid tissue or tissues
36.30
73051
Cytology material obtained directly from a patient by fine needle aspiration of solid tissue or tissues if:
(a) the aspiration is performed by a recognised pathologist; or
(b) a recognised pathologist attends the aspiration and performs cytological examination during the attendance
68.00
73053
Cytology of smears from cervix:
(a) for detection of precancerous or cancerous changes in women with no symptoms, signs or recent history suggestive of cervical neoplasia; or
(b) due to an unsatisfactory smear taken in the circumstances defined in para (a) above ;
each examination
12.40
73055
Cytology not associated with item 73053, of smears from cervix in association with:
(a) the management of previously detected abnormalities including precancerous or cancerous conditions; or
(b) the investigation of women with symptoms, signs or recent history suggestive of cervical neoplasia;
each test
12.40
73057
Cytology of smears from vagina, not associated with item 73053 or 73055 nor to monitor hormone replacement therapy—each test
12.40
GROUP P7—CYTOGENETICS
73287
Chromosome studies including preparation, count, karyotyping and identification by banding techniques or fragile X-site determination of one or more of any tissue or fluid except blood—1 or more tests
323.50
73289
Chromosome studies including preparation, count, karyotyping and identification by banding techniques or fragile X-site determination of blood—1 or more tests
293.15
GROUP P8—INFERTILITY AND PREGNANCY TESTS
73521
Semen examination for presence of spermatozoa, or examination of cervical mucus for spermatozoa (Huhner’s test)
6.70
73523
Semen examination (other than post-vasectomy semen examination), including:
(a) measurement of volume, sperm count, and motility; and
(b) examination of stained preparations; and
(c) morphology; and (if performed)
(d) differential count and 1 or more chemical tests;
with a maximum of 4 episodes in a 12-month period—each episode
27.90
73525
Sperm antibodies—sperm-penetrating ability—1 or more tests
17.95
73527
Chorionic gonadotrophin (beta-HCG)— detection in serum or urine by 1 or more methods, including serial dilution if performed, for diagnosis of pregnancy—1 or more tests
9.80
73529
Chorionic gonadotrophin (beta-HCG)—quantitation in serum by 1 or more methods for diagnosis of hydatidiform mole, HCG-secreting neoplasm, or threatened abortion, or follow-up of abortion or diagnosis of ectopic pregnancy, including any services performed in 73529—1 test
27.90
GROUP P9—SIMPLE BASIC PATHOLOGY TESTS
73801
Semen examination for presence of spermatozoa
6.40
73802
Leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count), haemoglobin, haematocrit or erythrocyte count—1 test
4.25
73803
2 tests described in item 73802
5.60
73804
3 or more tests described in item 73802
7.65
73805
Microscopy of urine whether stained or not, or catalase test
4.25
73806
Pregnancy test by 1 or more immunochemical methods
10.45
73807
Microscopy for wet film other than urine, including any relevant stain
6.40
73808
Microscopy of Gram-stained film, including (if performed) a service described in item 73805 or 73807
8.05
73809
Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method
2.15
73810
Microscopy for fungi in skin, hair or nails—1 or more sites
6.40
73811
Mantoux test
10.45
GROUP P10—PATIENT EPISODE INITIATION
73901
Initiation of a patient episode that consists only of a service described in item 73053, 73055 or 73057 from a person who is not in a recognised hospital or a prescribed laboratory
7.75
73903
Initiation of a patient episode that consists only of a service described in item 72801 from a person who is an in-patient of a hospital other than a recognised hospital
13.95
73905
Initiation of a patient episode that consists only of a service described in item 72801 from a person who is not an in-patient of a private hospital and not a patient of a recognised hospital
7.75
73907
Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected in a licensed collection centre
16.05
73909
Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person who is an in-patient of a hospital other than a recognised hospital
16.05
73911
Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in the place where the person was residing or in a nursing home or institution
16.05
73913
Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or 73907 or items in Group P9) if the specimen is collected from the person by the person
9.85
73915
Initiation of a patient episode by collection of a specimen for a service (other than a service described in items 73901, 73903 or 73905 or items in Group P9) if the specimen is collected by or on behalf of the treating practitioner
9.85
GROUP P11—SPECIMEN REFERRED
73921
Referral of a specimen by an approved pathology practitioner of an approved pathology authority to another approved pathology practitioner of another approved pathology authority or to another approved pathology authority
9.85
part 3—ABBREVIATIONS
DIVISION A—ABBREVIATIONS FOR GROUPS OF TESTS
Group
Tests included in group
Abbreviation
Item numbers
Cardiac enzymes
Lactate dehydrogenase (LDH), aspartate aminotransferase (AST) and creatine kinase (CK)
CE
66205
Coagulation studies
Prothrombin time, activated partial thrombo-plastin time and two or more of the following tests—bleeding time, thrombin clotting time, fibrinogen degradation products, fibrin monomer, D-dimer, factor XIII screening tests
COAG
65035
Electrolytes
Sodium (NA), potassium (K), chloride (Cl), and bicarbonate (HCO3)
E
66207
Lipid studies
Cholesterol (CHOL) and triglycerides (TRIG)
FATS
66331
Liver function tests
Alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), bilirubin (BIL), gamma glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), and protein (PROT)
LFT
66211
Group
Tests included in group
Abbreviation
Item numbers
Syphilis serology
Rapid plasma reagin test (RPR), or venereal disease research laboratory test (VDRL), and treponema pallidum haemagglutination test (TPHA), or fluorescent treponemal antibody-absorption test (FTA)
STS
69231
Urea, electrolytes, creatine
Urea, electrolytes, creatinine
U&E
66211
DIVISION B—ABBREVIATIONS FOR INDIVIDUAL TESTS
Test Abbreviation Item
Abnormal haemoglobins AH 65027
Acetoacetate ACAT 66367
Acetylcholine receptor—tissue antigens—antibodies ARA 71109
Actinomycetes—microbial antibody testing ACT 69229
Adenovirus—microbial antibody testing ADE 69229
Adrenal cortex—tissue antigens—antibodies ADR 71109
Adrenocorticotrophic hormone (ACTH) ACTH 66405
AFB microscopy and culture of sputum AFB 69213
Alanine aminotransferase ALT 66201
Albumin ALB 66201
Alcohol (ethanol) ETOH 66367
Aldosterone ALDS 66405
Alkaline phosphatase ALP 66201
Alkaline phosphatase—isoenzymes ALPI 66249
Alpha fetoprotein AFP 66353
Alpha fetoprotein—for Down's syndrome and neural tube defect testing NTDD 66321
Alpha‑1‑acid glycoprotein AAG 66255
Alpha-1-antitrypsin AAT 66255
Alpha‑2‑macroglobulin AMG 66255
Aluminium AL 66277
Aluminium—renal dialysis ALR 66325
Amino acids AA 66367
Amiodarone AMIO 66235
Amitriptyline AMIT 66235
Ammonia NH3 66367
Amniotic fluid examination AFE 66243
Amylase AMS 66201
Amylobarb AMYL 66235
Androstenedione ANDR 66405
Angiotensin converting enzyme ACE 66367
Antibiotic and antimicrobial chemotherapeutic agents—quantitation QAA 69251
Antibodies to extractable nuclear antigens—detection ENA 71101
Antibodies to extractable nuclear antigens—characterisation of antibodies if positive ENA ENAP 71103
Antibodies to nuclear antigens—detection ANA 71097
Antibodies to nuclear antigens—quantitation and measurement of DNA binding if positive ANA ANAP 71099
Antibodies to tissue antigens—acetylcholine receptor ARA 71109
Antibodies to tissue antigens—adrenal cortex ADR 71109
Antibodies to tissue antigens—cardiolipin ACL 71109
Antibodies to tissue antigens—centromere ACA 71119
Antibodies to tissue antigens—gastric parietal cell PCA 71119
Antibodies to tissue antigens—gliadin IgA GLIA 71119
Antibodies to tissue antigens—glomerular basement membrane GBA 71109
Antibodies to tissue antigens—heart AHE 71109
Antibodies to tissue antigens—histone AHI 71109
Antibodies to tissue antigens—insulin receptor antibodies INSA 71109
Antibodies to tissue antigens—intercellular cement substance of skin ICCS 71109
Antibodies to tissue antigens—intrinsic factor AIF 71109
Antibodies to tissue antigens—islet cell AIC 71109
Antibodies to tissue antigens—Jo‑1 JO1 71119
Antibodies to tissue antigens—keratin KERA 71119
Antibodies to tissue antigens—liver/kidney microsomes LKA 71119
Antibodies to tissue antigens—lymphocyte ALY 71109
Antibodies to tissue antigens—mitochondria MA 71119
Antibodies to tissue antigens—neuron ANE 71109
Antibodies to tissue antigens—neutrophil cytoplasm ANCA 71109
Antibodies to tissue antigens—ovary AOV 71109
Antibodies to tissue antigens—parathyroid PTHA 71109
Antibodies to tissue antigens—platelet APA 71109
Antibodies to tissue antigens—PM‑Sc1 PM1 71119
Antibodies to tissue antigens—reticulin RCA 71119
Antibodies to tissue antigens—salivary gland ASG 71109
Antibodies to tissue antigens—Scl‑70 SCL 71119
Antibodies to tissue antigens—skeletal muscle SLA 71109
Antibodies to tissue antigens—skin basement membrane SKA 71109
Antibodies to tissue antigens—smooth muscle SMA 71119
Antibodies to tissue antigens—thyroglobulin ATG 71109
Antibodies to tissue antigens—thyroid icrosome TMA 71109
Antibodies to tissue antigens—TSH receptor antibody test TSHA 71109
Antibody testing, microbial (see Microbial)
Antigen testing, microbial (see Microbial)
Antithrombin III ATH 65037
Anus—cytology on specimens from SMCY 73043
Apolipoprotein B/A1 ratio APO 66317
Arginine infusion ARIN 66297
Arsenic AS 66277
Aspartate aminotransferase AST 66201
Aspergillus—microbial antibody testing ASP 69229
Avian precipitins (bird fancier’s disease)—microbial antibody testing APP 69229
B12 vitamin RCF 66267
Barbiturate BARB 66235
Beryllium BE 66277
Beta‑hydroxybutyrate BHYB 66367
Beta‑2‑microglobulin BMIC 66361
Bicarbonate HCO3 66201
Bilirubin (all fractions) BILI 66201
Bilirubin (all fractions)—in urine UBIL 66213
Bilirubin (all fractions)—neonatal BILN 66365
Bird fancier’s disease (see avian precipitins)
Blastomyces—microbial antibody testing BLM 69229
Bleeding time BT 65029
Blood—compatibility testing XMAT 65023
Blood—culture BC 69215
Blood—film BF 65005
Blood—full examination FBE 65001
Blood—gases GAS 66225
Blood—group and blood group antibodies BGAB 65021
Blood—group antibodies BGA 65025
Blood—group systems BGS 65019
Blood—grouping‑ABO and RH (D antigen) BG 65017
Blood—viscosity VISC 65001
Body cavities, aspirations of—microscopy and culture of material from MCS3 69209
Body fluids—cytology BFCY 73045
Bone marrow examination—aspirate BMEA 65015
Bone marrow examination—trephine BMET 65013
Bordetella pertussis—microbial antibody testing BOR 69229
Borrelia burgdorferi—microbial antibody testing BOB 69229
Breath hydrogen test BHT 66283
Bromide BRMD 66235
Brucella—microbial antibody testing BRU 69229
C‑l esterase inhibitor—quantitation CEIQ 66257
C‑l esterase inhibitor—functional CEIF 66258
C‑Peptide CPEP 66405
C‑reactive protein CRP 65001
CA‑15.3 antigen CA15 66261
CA‑l9.9 antigen CA19 66261
CA‑125 antigen C125 66261
Cadmium CD 66277
Caeruloplasmin CPLS 66361
Calcitonin CALT 66405
Calcium (total, dialysed or ionized) CA 66201
Calculus analysis CALC 66229
Campylobacter jejuni—microbial antibody testing CAM 69229
Candida—microbial antibody testing CAN 69229
Carbamazepine (Tegretol) CARB 66235
Carboxyhaemoglobin COHB 65027
Carcinoembryonic antigen CEA 66261
Cardiac enzymes (see group tests in Division A)
Cardiolipin—tissue antigens—antibodies ACL 71109
Catecholamines CAT 66281
Cell mediated immunity—delayed type—hypersensitivity test CMI 71137
Centromere—tissue antigens—antibodies ACA 71119
Cervix—cytology—routine CCR 73053
Cervix—cytology—abnormalities CCRA 73055
Cervix—microscopy and culture of material from MCS2 69207
Characterisation of antibodies if positive ENA ENAP 71103
Chemicals, toxic (ingested or absorbed)—assays DRGO 66231
Chlamydia—direct detection from clinical material CHLY 69221
Chlamydia—investigation by cultural methods CHLC 69261
Chlamydia—investigation by DNA probe CHLP 69261
Chlamydia—microbial antibody testing CHL 69229
Chlamydia—microbial antigen testing CHLY 69221
Chloral hydrate CHHY 66235
Chlorazepate CHZP 66235
Chloride CL 66201
Chloroquine CLOQ 66235
Chlorpromazine CHLO 66235
Cholesterol CHOL 66331
Cholesterol—HDL HDLC 66317
Cholinesterase CHSE 66367
Chorionic gonadotrophin—for pregnancy diagnosis HCG 73527
Chorionic gonadotrophin—for diagnosis of specified conditions HCGD 73529
Chorionic gonadotrophin—for Down's syndrome and neural tube defect testing NTDD 66321
Chromium CR 66277
Chromosome identification and banding 73287-89
Chromosome identification studies—blood CSB 73289
Chromosome identification studies—other than blood CS 73287
Cimetidine CMTD 66235
Clobazam CLOB 66235
Clomipramine CLOM 66235
Clonazepam (Rivotril) CLON 66235
Clostridium difficile—microbial antigen testing CLDT 69219
Coagulation—factors (see individual factors)
Coagulation—studies (see group tests in Division A)
Coagulation—time CT 65029
Coccidioides—microbial antibody testing CCC 69229
Cold agglutinins CAG 65005,
65027
Collection of specimen(s) for cytological examination 73051
Compatibility testing XMAT 65023
Complement, total haemolytic COM 71081
Complement, total haemolytic—components C3 C3 71083
Complement, total haemolytic—components C4 C4 71083
Complement, total haemolytic—properdin factor B PFB 71083
Complement, total haemolytic—other components COMP 71089
Copper CU 66277
Cortisol CORT 66405
Coxsackie B1‑6—microbial antibody testing COX 69229
Creatine kinase CK 66201
Creatine kinase—isoenzymes CKI 66201
Creatine kinase—isoenzymes (electrophoresis) CKIE 66249
Creatinine C 66201
Cryofibrinogen—qualitative CFID 66213
Cryofibrinogen—quantitative CFIE 66215
Cryoglobulins—qualitative CGLD 66213
Cryoglobulins—quantitative CGLE 66215
Cryoglobulins—investigation by immunoelectrophoresis or immunofixation RYO 71061
Cryptococcal antigen—microbial antigen testing CRYN 69219
Cryptococcus—microbial antibody testing CRY 69229
CSF—microscopy and culture of material from MCS3 69209
CSF antigens—group B streptococcus STB 69219
CSF antigens—Haemophilus influenzae HI 69219
CSF antigens—Neisseria meningitidis NMG 69219
CSF antigens—Streptoccus pneumoniae SPN 69219
Cultural examination of faeces FCS 69211
Cyclic AMP CAMP 66405
Cyclosporin A CLSA 66235
Cystine—qualitative UCYS 66213
Cystine—quantitative CYST 66367
Cytology—from body fluids, sputum (1 specimen), urine, washings or brushings BFCY 73045
Cytology—from cervix—routine CCR 73053
Cytology—from cervix—abnormalities CCRA 73055
Cytology—from fine needle aspiration of solid tissues FNCY 73049
Cytology—from fine needle aspiration of solid tissues—aspiration or attendance by a pathologist FNCP 73051
Cytology—from skin, nipple discharge, lip, mouth, nose or anus SMCY 73043
Cytology—from vagina CVO 73057
Cytology—from 3 sputum or urine specimens SPCY 73047
Cytomegalovirus—microbial antibody testing CMV 69229
Cytomegalovirus serology in pregnancy—microbial antibody testing CMVP 69253‑57
D‑dimer test DD 65029
D vitamin VITD 66271
Dehydroepiandrosterone sulphate (DHEAS) DHEA 66405
Dengue—microbial antibody testing DEN 69229
11-Deoxycortisol DCOR 66405
Desipramine DESI 66235
Dexamethasone DXST 66295
Dexamethasone—suppression test DEXA 66295
DHEAS (Dehydroepiandrosterone sulphate) DHEA 66405
Diazepam DIAZ 66235
Differential cell count DIFF 65005
Digoxin DIG 66235
Dihydrotesterone DHTS 66405
Diphenylhydantoin (Dilantin) DIL 66235
Diphtheria—microbial antibody testing DIP 69229
Direct Coombs test CMBS 65005,
65027
Disopyramide (Rythmodan) DISO 66235
DNA, double‑stranded antibodies DNAD 71099
DNA binding—quantitation and measurement if positive ANA ANAP 71099
Down's syndrome and neural tube defects NTDD 66321
Doxepin hydrochloride DOXE 66235
Drugs—abuse treatment programme—assay DATP 66343
Drugs—inappropriate dosage—assay DRGO 66231
Drugs—therapeutic—assay (see individual drugs)
Dynamic function tests GHSE 66295
Ear—microscopy and culture of material from MCS1 69205
Echinococcus—microbial antibody testing ECC 69229
Echo‑coxsackie group—microbial antibody testing ECH 69229
Electrolytes (see group tests in Division A)
Electron microscopy of biopsy material EM 72807
Electrophoresis, to demonstrate—creatine kinase isoenzymes CKIE 66249
Electrophoresis, to demonstrate—lactate dehydrogenase isoenzymes LDI 66249
Electrophoresis, to demonstrate—protein classes, or paraprotein EPP1 66249,
66250
Electrophoresis, to demonstrate—protein classes or presence and amount of paraprotein classes, concurrent collection EPP2 66247
Elements (see individual elements)
Entamoeba histolytica—microbial antibody testing AMO 69229
Enzyme assays of solid tissue or tissues ENZS 66285
Epstein Barr virus—microbial antibody testing EBV 69229
Erythrocyte—assessment of haemolysis ERYH 65009
Erythrocyte—assessment of metabolic enzymes ERYM 65009
Erythrocyte—count RCC 65001
Erythrocyte—sedimentation rate ESR 65001
Ethosuximide (Zarontin) ETHO 66235
Euglobulin clot lysis time ECLT 65037
Extractable nuclear antigens—detection of antibodies to ENA 71101
Eye—microscopy and culture of material from MCS1 69205
Factor II FII 65045
Factor V FV 65045
Factor VII FVII 65045
Factor VIII VIII 65045
Factor IX FIX 65045
Factor X FX 65045
Factor XI FXI 65045
Factor XII FXII 65045
Factor XIII XIII 65045
Factor XIII deficiency test F13D 65029
Faecal fat FFAT 66283
Faecal fat—haemoglobin—chemical test FHC 66217
Faecal fat—haemoglobin—immunological test FHI 66219
Faecal fat—porphyrins—qualitative test FPR 66217
Faecal fat—reducing substances FRS 66217
Faeces—culture FCS 69211
Faeces—microscopy for parasites OCP 69203
Fatty acids—total free—quantitation TFFA 66367
Ferritin (see also Iron studies) FERR 66355
Fibrin monomer FM 65029
Fibrinogen FIB 65029
Fibrinogen—degradation products FDP 65029
Fitzgerald factor FGF 65045
Flecainide FLEC 66235
Fletcher factor FF 65045
Fluorescent treponemal antibody—absorption test (FTA‑ABS)—microbial antibody testing FTA 69229
Fluoxetine FLUX 66235
Folate—red cell RCF 66267
Follicle stimulating hormone (FSH) FSH 66405
Frozen section diagnosis of biopsy material FS 72803
Fructosamine FRUC 66201
Full blood examination FBE 65007
Gamma glutamyl transpeptidase GGT 66201
Gastric parietal cell—tissue antigens—antibodies PCA 71119
Gastrin GAST 66405
Gliadin IgA—tissue antigens—antibodies GLIA 71119
Globulin GLOB 66201
Glomerular basement membrane—tissue antigens—antibodies GBA 71109
Glucagon GLGO 66405
Glucagon stimulation test GSTC 66297
Glucose GLUC 66201
Glucose—tolerance test GTT 66201
Glycolated haemoglobin (Hb A1c) GHB 66319
Glycosylated haemoglobin (Hb A1c) GHB 66319
Gold AU 66277
Gonadotrophin GRHS 66297
Group B streptococcus—CSF antigens STB 69219
Group B streptococcus—microbial antigen testing STB 69219
Group P9—simple basic pathology tests 73801‑11
Growth hormone GH 66405
Growth hormone—stimulation by exercise or L‑dopa GHSE 66295
Growth hormone—suppression by dexamethasone or glucose GHSG 66295
Haematocrit HCT 65001
Haemoglobin HB 65001
Haemoglobin—in urine UHB 66213
Haemoglobinopathy tests HMGP 65011
Haemophilus influenzae antigens HI 69219
Haemophilus influenzae—microbial antibody testing HUS 69229
Haemophilus influenzae—microbial antigen testing HI 69219
Haloperidol HALO 66235
Haptoglobins HGLB 66361
HDL cholesterol HDLC 66317
Heart—tissue antigens—antibodies AHE 71109
Heparin—cofactor II HRNC 65037
Heparin—test HEPR 65043
Hepatitis delta antibody—anti‑delta—microbial antibody testing HDA 69229
Hepatitis serology—acute hepatitis HEP 69247
Hepatitis serology—follow‑up of proven hepatitis B HEPB 69249
Hepatitis serology—hepatitis B serology to define immune status HEP1 69245
Hepatitis serology—hepatitis B surface antigen HBsAg HBSA 69243
Hepatitis serology—hepatitis C HEPC 69265
Hepatitis serology—hepatitis delta antibody HDA 69229
Hepatitis serology—in pregnancy HEPP 69253‑57
Herpes simplex virus—direct detection from clinical material HSV 69223
Herpes simplex virus—investigation by culture HSVC 69263
Herpes simplex virus—microbial antibody testing HPA 69229
Herpes simplex virus—microbial antigen testing HSV 69223
Heterophile antibodies IM 65005,
65027
HIAA (hydroxyindoleacetic acid) HIAA 66367
Histamine HIAM 66367
Histone—tissue antigens—antibodies AHI 71109
Histopathology of biopsy material HIST 72801
Histoplasma—microbial antibody testing HIP 69229
HLA typing—HLA‑B27 HLAB 71147
HLA typing—HLA class 1 HLA1 71149
HLA typing—HLA class 2 HLA2 71151
HMMA (hydroxy‑3‑methoxymandelic acid, previously known as VMA) HMMA 66281
HMPG (hydroxy-methoxy-phenylethylene glycol) HMPG 66281
Homovanillic acid HVA 66281
Hormone receptor assay—breast HRA 66315
Hormone receptor assay—ovary HRO 66315
Hormones—adrenocorticotrophic ACTH 66405
Hormones—aldosterone ALDS 66405
Hormones—androstanedione ANDR 66405
Hormones—C‑Peptide CPEP 66405
Hormones—calcitonin CALT 66405
Hormones—cortisol CORT 66405
Hormones—cyclic AMP CAMP 66405
Hormones—dehydroepiandrosterone sulphate (DHEAS) DHEA 66405
Hormones—dihydrotestosterone DHTS 66405
Hormones—follicle stimulating hormone FSH 66405
Hormones—gastrin GAST 66405
Hormones—glucagon GLGO 66405
Hormones—gonadotrophin GRHS 66297
Hormones—growth hormone GH 66405
Hormones—growth hormone—stimulation by exercise or L‑dopa GHSE 66295
Hormones—growth hormone—suppression by dexamethasone or glucose GHSG 66295
Hormones—hormone receptor assay—breast HRA 66315
Hormones—hormone receptor assay—ovary HRO 66315
Hormones—human chorionic gonadotrophin—for pregnancy diagnosis HCG 73527
Hormones—human chorionic gonadotrophin (see human chorionic gonadotrophin)
Hormones—human placental lactogen HPL 66373
Hormones—hydroxyprogesterone OHP 66405
Hormones—insulin INS 66405
Hormones—insulin, hypoglycaemia test INHY 66297
Hormones—luteinising hormone LH 66405
Hormones—oestradiol E2 66405
Hormones—oestriol E3 66373
Hormones—oestrone E1 66405
Hormones—parathyroid hormone PTH 66405
Hormones—pentagastrin PSTR 66297
Hormones—progesterone PROG 66405
Hormones—prolactin PROL 66405
Hormones—renin REN 66405
Hormones—sex hormone binding globulin SHBG 66405
Hormones—somatomedin SOMA 66405
Hormones—testosterone TES 66405
Hormones—thyroid stimulating hormone (where not requested on its own or as part of TFTs) TSH 66371,
66405
Hormones—urine steroid fraction or fractions USF 66405
Hormones—vasoactive intestinal peptide VIP 66405
Hormones—vasopressin ADH 66405
Hormones—11 deoxycortisol DCOR 66405
Hormones and hormone binding proteins (see individual hormones and proteins) 66405
Huhner’s test HT 73521
Human chorionic gonadotrophin—for pregnancy diagnosis HCG 73527
Human chorionic gonadotrophin—for diagnosis of specified conditions HCGD 73529
Human chorionic gonadotrophin—for Down's syndrome and neural tube defect testing NTDD 66321
Human placental lactogen HPL 66373
HVA (homovanillic acid) HVA 66281
Hydatid—microbial antibody testing HYD 69229
Hydroxy methoxy phenylethylene glycol HMPG 66281
Hydroxy‑3‑methoxymandelic acid, previously known as VMA) HMMA 66281
Hydroxychloroquine HOCQ 66235
Hydroxyindoleacetic acid HIAA 66367
Hydroxyprogesterone OHP 66405
Hydroxyproline HYDP 66367
Imipramine IMIP 66235
Immediate frozen-section diagnosis of biopsy material FS 72803
Immunoglobulins—A IGA 71067
Immunoglobulins—D IGD 71067
Immunoglobulins—E (total) IGE 71075‑79
Immunoglobulins—G IGG 71067
Immunoglobulins—G, 4 subclasses SIGG 71073
Immunoglobulins—M IGM 71067
Immunohistochemical investigation of biopsy material HIS 72805
Infectious mononucleosis IM 69229
Influenza A—microbial antibody testing FLA 69229
Influenza B—microbial antibody testing FLB 69229
Insulin INS 66405
Insulin—hypoglycaemia test INHY 66297
Insulin—tissue antigens—antibodies AINS 71109
Insulin receptor antibodies—tissue antigens—antibodies INSA 71109
Intercellular cement substance of skin—tissue antigens—antibodies ICCS 71109
Intestinal disaccharidases INTD 66283
Intrinsic factor—tissue antigens—antibodies AIF 71109
Iron studies (iron, transferrin and ferritin) IS 66263
Islet cell—tissue antigens—antibodies AIC 71109
Jo‑1—tissue antigens—antibodies JO1 71119
Keratin—tissue antigens—antibodies KERA 71119
L‑dopa GHLD 66295
Lactate LACT 66367
Lactate—dehydrogenase LDH 66201
Lactate—dehydrogenase isoenzymes LDI 66249
Lamellar body phospholipid LBPH 66243
Lead PB 66279
Lecithin/sphingomyelin ratio (amniotic fluid) LS 66243
Legionella pneumophila—serogroup 1—microbial antibody testing LP1 69229
Legionella pneumophila—serogroup 2—microbial antibody testing LP2 69229
Leishmaniasis—microbial antibody testing LEI 69229
Leptospira—microbial antibody testing LEP 69229
Leucocyte count WCC 65001
Leucocyte—3 surface markers—blood, CSF, serous fluid LMH3 71139
Leucocyte—3 surface markers—tissue LMT3 71141
Leucocyte—6 surface markers—blood, CSF, serous fluid or tissue LM6 71143
Leucocyte—6 surface markers—blood, CSF, serous fluid and tissue (s) LMHT 71145
Lignocaine LIGN 66235
Lip—cytology on specimens from SMCY 73043
Lipase LIP 66201
Lipid studies (see group tests in Division A)
Lipoprotein electrophoresis LEPG 66250
Listeria—microbial antibody testing LIS 69229
Lithium LI 66201
Liver function tests (see group tests) LFT 66211
Liver/kidney microsomes—tissue antigens—antibodies LKA 71119
Lupus anticoagulant LUPA 65037
Luteinising hormone LH 66405
Lymphocyte—tissue antigens—antibodies ALY 71109
Lymphocytes—functional tests—1 test LF1 71127
Lymphocytes—functional tests—2 tests LF2 71129
Lymphocytes—functional tests—3 tests LF3 71131
Magnesium MG 66201
Mammary serum antigen MSA 66261
Manganese MN 66277
Mantoux test MANT 73811
Measles—microbial antibody testing MEA 69229
Melanogen (see Urine melanin)
Mercury HG 66277
Metalbumin detection (Schumm’s test) SCHM 65027
Metanephrines MNEP 66281
Methadone MTDN 66235
Methotrexate MTTA 66235
Methsuximide MSUX 66235
Metronidazole MRDZ 66235
Mexiletine (Mexitil) MEX 66235
Mianserin MIAS 66235
Microalbumin MALB 66361
Microbial antibody testing—actinomycetes ACT 69229
Microbial antibody testing—adenovirus ADE 69229
Microbial antibody testing—aspergillus ASP 69229
Microbial antibody testing—avian precipitins (see avian precipitions)
Microbial antibody testing—Blastomyces BLM 69229
Microbial antibody testing—Bordetella pertussis BOR 69229
Microbial antibody testing—Borrelia burgdorferi BOB 69229
Microbial antibody testing—Brucella BRU 69229
Microbial antibody testing—Campylobacter jejuni CAM 69229
Microbial antibody testing—Candida CAN 69229
Microbial antibody testing—Chlamydia CHL 69229
Microbial antibody testing—Coccidioides CCC 69229
Microbial antibody testing—Coxsackie B1‑6 COX 69229
Microbial antibody testing—cryptococcus CRY 69229
Microbial antibody testing—cytomegalovirus CMV 69229
Microbial antibody testing—cytomegalovirus serology in pregnancy CMVP 69253‑57
Microbial antibody testing—dengue DEN 69229
Microbial antibody testing—diphtheria DIP 69229
Microbial antibody testing—echinococcus ECC 69299
Microbial antibody testing—echo‑coxsackie group ECH 69229
Microbial antibody testing—Entamoeba histolytica AMO 69229
Microbial antibody testing—Epstein Barr virus EBV 69229
Microbial antibody testing—fluorescent treponemal antibody—absorption test (FTA‑ABS) FTA 69229
Microbial antibody testing—Haemophilus influenzae HUS 69229
Microbial antibody testing—hepatitis C HEPC 69265
Microbial antibody testing—hepatitis delta antibody—anti‑delta HDA 69229
Microbial antibody testing—herpes HPA 69229
Microbial antibody testing—Histoplasma HIP 69229
Microbial antibody testing—hydatid HYD 69229
Microbial antibody testing—infectious mononucleosis IM 69229
Microbial antibody testing—influenza A FLA 69229
Microbial antibody testing—influenza B FLB 69229
Microbial antibody testing—Legionella pneumophila—serogroup 1 LP1 69229
Microbial antibody testing—Legionella pneumophila—serogroup 2 LP2 69229
Microbial antibody testing—leishmaniasis LEI 69229
Microbial antibody testing—Leptospira LEP 69229
Microbial antibody testing—Listeria LIS 69229
Microbial antibody testing—measles MEA 69229
Microbial antibody testing—Micropolyspora faeni MIC 69229
Microbial antibody testing—mumps MUM 69229
Microbial antibody testing—Murray Valley encephalitis MVE 69229
Microbial antibody testing—Mycoplasma pneumoniae MYC 69229
Microbial antibody testing—Neisseria menigitidis MEN 69229
Microbial antibody testing—Newcastle disease NCD 69229
Microbial antibody testing—parainfluenza 1 PF1 69229
Microbial antibody testing—parainfluenza 2 PF2 69229
Microbial antibody testing—parainfluenza 3 PF3 69229
Microbial antibody testing—paratyphi PTY 69229
Microbial antibody testing—pertussis PER 69229
Microbial antibody testing—poliomyelitis PLO 69229
Microbial antibody testing—Proteus OX 19 POX 69229
Microbial antibody testing—Proteus OXK POK 69229
Microbial antibody testing—Q fever QFF 69229
Microbial antibody testing—rapid plasma reagin test RPR 69229
Microbial antibody testing—respiratory syncytial virus RSV 69229
Microbial antibody testing—Ross River virus RRV 69229
Microbial antibody testing—rubella RUB 69229
Microbial antibody testing—Salmonella typhi (H) SAH 69229
Microbial antibody testing—Salmonella typhi (O) SAO 69229
Microbial antibody testing—Schistosoma STO 69229
Microbial antibody testing—streptococcal serology—anti‑DNASE B titre ADNB 69229
Microbial antibody testing—streptococcal serology—anti‑streptolysin O titre ASOT 69229
Microbial antibody testing—Streptococcus pneumoniae PCC 69229
Microbial antibody testing—tetanus TET 69229
Microbial antibody testing—Thermoactinomyces vulgaris THE 69229
Microbial antibody testing—thermopolyspora TPS 69229
Microbial antibody testing—Toxocara TOC 69229
Microbial antibody testing—toxoplasma TOX 69229
Microbial antibody testing—TPHA (Treponema pallidum haemagglutination test) TPHA 69229
Microbial antibody testing—trichinosis TOS 69229
Microbial antibody testing—typhus, Weil‑Felix TYP 69229
Microbial antibody testing—Varicella zoster VCZ 69229
Microbial antibody testing—VDRL (Venereal Disease Research Laboratory) VDRL 69229
Microbial antibody testing—Yersinia enterocolitica YER 69229
Microbial antigen testing—Chlamydia CHLY 69221
Microbial antigen testing—Clostridium difficile CLDT 69219
Microbial antigen testing—group B streptococcus STB 69219
Microbial antigen testing—Haemophilus influenzae HI 69219
Microbial antigen testing—herpes simplex virus HSV 69263
Microbial antigen testing—Neisseria gonorrhoeae GON 69219
Microbial antigen testing—Neisseria meningitidis NMG 69219
Microbial antigen testing—respiratory syncytial virus RSVN 69219
Microbial antigen testing—Streptococcus pneumoniae SPN 69219
Microbial antigen testing—Varicella zoster VCZN 69219
Micropolyspora faeni MIC 69229
Microscopic examination of—faeces for parasites OCP 69203
Microscopic examination of—material other than blood M 69201
Microscopy and culture of—material from nose, throat, eye or ear MCS1 69205
Microscopy and culture of—material from skin, superficial sites, urethra, vagina, cervix or rectum MCS2 69207
Microscopy and culture of—post‑op wounds, aspirations of body cavities, synovial fluid, CSF and op/biopsy specimens MCS3 69209
Microscopy and culture of—specimens of sputum MCS2 69207
Microscopy and culture of—specimens of sputum, urine or other body fluids for mycobacteria AFB 69213
Microscopy, culture, identification and sensitivity of urine UMCS 69217
Mitochondria—tissue antigens—antibodies MA 71119
Mouth—cytology on specimens from SMCY 73043
Mucin‑like carcinoma-associated antigen MCA1 66261
Mumps—microbial antibody testing MUM 69229
Murray Valley encephalitis—microbial antibody testing MVE 69229
Mycobacteria microscopy and culture of sputum AFB 69213
Mycoplasma pneumoniae—microbial antibody testing MYC 69229
Myoglobin in urine UMY 66213
N‑acetyl procainamide NAPC 66235
Neisseria gonorrhoeae—microbial antigen testing GON 69219
Neisseria menigitidis antigens NMG 69219
Neisseria menigitidis—microbial antibody testing MEN 69229
Neisseria menigitidis—microbial antigen testing NMG 69219
Neural tube defects and Down's syndrome NTDD 66321
Neuron—tissue antigens—antibodies ANE 71109
Neuron specific enolase NSEN 66261
Neutrophil cytoplasm—tissue antigens—antibodies ANCA 71109
Neutrophil functions NFT 71135
Newcastle disease—microbial antibody testing NCD 69229
Nickel NI 66277
Nipple discharge—cytology on specimens from SMCY 73043
Nitrazepam NITR 66235
Nordothiepin NDIP 66235
Norfluoxetine NFLE 66235
Nortriptyline NORT 66235
Nose—cytology on specimens from SMCY 73043
Nose—microscopy and culture of material MCS1 69205
Nuclear antigens—detection of antibodies to ANA 71097
Oestradiol E2 66405
Oestriol E3 66373
Oestriol—for Down's syndrome and neural tube defect testing NTDD 66321
Oestrone E1 66405
Oligoclonal proteins OGP 71065
Op/biopsy specimens—microscopy and culture of material from MCS3 69209
Osmolality—serum or urine OSML 66223
Ovary—tissue antigens—antibodies AOV 71109
Oxalate OXAL 66367
Oxazepam OXAZ 66235
PAA (phenyl acetic acid) PAA 66281
Palmitic acid in amniotic fluid PALM 66243
Pap smear CCR 73053
Papanicolaou test CCR 73053
Paracetamol PARA 66235
Parainfluenza 1—microbial antibody testing PF1 69229
Parainfluenza 2—microbial antibody testing PF2 69229
Parainfluenza 3—microbial antibody testing PF3 69229
Paraprotein investigation—by electrophoresis EPPI 66249
Paraprotein investigation—by immunoelectrophoresis or immunofixation PPRO 71061
Paraprotein investigation—on concurrently collected serum or urine PPSU 71063
Paraquat PARQ 66235
Parasites—microscopic examination of faeces OCP 69203
Parathyroid hormone (PTH) PTH 66405
Parathyroid—tissue antigens—antibodies PTHA 71109
Paratyphi—microbial antibody testing PTY 69229
Partial thromboplastin time PTT 65029
Passovy factor PF 65045
Patient episode initiation PEI 73901‑15
Pentagastrin PSTR 66297
Pentobarbitone PENT 66235
Perhexiline PHEX 66235
Pertussis—microbial antibody testing PER 69229
pH measurement of body fluids other than urine PH 66213
Phenobarbitone PHBA 66235
Phensuximide PHEN 66235
Phenylacetic acid PAA 66281
Phenytoin PHEY 66235
Phosphate PHOS 66201
Phosphatidylglycerol PTGL 66243
Plasminogen PLAS 65037
Platelet—aggregation PLTG 65041
Platelet—count PLTC 65001
Platelet—tissue antigens—antibodies APA 71109
PM‑Sc1—tissue antigens—antibodies PM1 71119
Poliomyelitis—microbial antibody testing PLO 69229
Porphobilingen in urine UPG 66213
Porphyrins—quantitative test, 1 or more fractions PR 66281
Porphyrins in urine—qualitative test UPR 66213
Potassium K 66201
Prealbumin PALB 66361
Prednisolone PRED 66235
Pregnancy serology—1 test MSP1 69253
Pregnancy serology—2 tests MSP2 69255
Pregnancy serology—3 tests MSP3 69257
Pregnancy testing 73805
Pregnancy testing—diagnosis HCG 73527
Pregnancy testing—diagnosis of specified conditions HCGD 73529
Pregnancy testing—for diagnosis of Down's syndrome and neural tube defect NTDD 66321
Primidone PRIM 66235
Procainamide PCAM 66235
Progesterone PROG 66405
Prolactin PROL 66405
Prominal PROM 66235
Propranolol PPNO 66235
Prostate specific antigen PSA 66357
Prostatic acid phosphatase ACP 66357
Protein—C PROC 65037
Protein—S PROS 65037
Protein, quantitation of—alpha fetoprotein AFP 66353
Protein, quantitation of—alpha fetoprotein—for Down's syndrome and neural tube defect testing NTDD 66321
Protein, quantitation of—alpha‑l‑antitrypsin AAT 66255
Protein, quantitation of—alpha‑2‑macroglobulin AMAC 66255
Protein, quantitation of—beta‑2‑microglobulin BMIC 66361
Protein, quantitation of—C‑l esterase inhibitor CEI 66257
Protein, quantitation of—caeruloplasmin CPLS 66361
Protein, quantitation of—classes by electrophoresis EPPI 66249
Protein, quantitation of—ferritin (see also Iron studies) FERR 66355
Protein, quantitation of—haptoglobins HGLB 66361
Protein, quantitation of—microalbumin MALB 66361
Protein, total—quantitation of PROT 66201
Proteus OX 19—microbial antibody testing POX 69229
Proteus OXK—microbial antibody testing POK 69229
Prothrombin time PT 65029
Pyruvate PVTE 66367
Q fever—microbial antibody testing QFF 69229
Quinalbarb QUIB 66235
Quinidine QUIN 66235
Quinine QNN 66235
Rapid plasma reagin test—microbial antibody testing RPR 69229
RAST RAST 71079
Rectum—microscopy and culture of material from MCS2 69207
Red cell folate and serum B12 and serum folate if required RCF 66267
Red cell porphyrins—qualitative test RCP 65027
Referred specimen fee 73921
Renin REN 66405
Respiratory syncytial virus—microbial antibody testing RSV 69229
Respiratory syncytial virus—microbial antigen testing RSVN 69219
Reticulin—tissue antigens—antibodies RCA 71119
Reticulocyte count RETC 65001
Rheumatoid factor RF 71106
Rheumatoid factor—quantitation RFQ 71106
Ross River virus—microbial antibody testing RRV 69229
RSV (respiratory syncytial virus)—microbial antigen testing RSVN 69219
RSV (respiratory syncytial virus)—microbial antibody testing RSV 69229
Rubella—serology RUB 69229
Salicylate—aspirin SALI 66235
Salivary gland—tissue antigens—antibodies ASG 71109
Salmonella typhi (H)—microbial antibody testing SAH 69229
Salmonella typhi (O)—microbial antibody testing SAO 69229
Schistosoma—microbial antibody testing STO 69229
Scl‑70—tissue antigens—antibodies SCL 71119
Secretin SSGR 66297
Selenium SE 66277
Semen examination SEE 73523
Semen examination—for spermatozoa (post vasectomy) SES 73521
Serology—in pregnancy (see Pregnancy serology)
Serotonin 5HT 66367
Serum—Bl2 B12 66265
Serum—folate (with Bl2) FOL 66265
Serum—folate (with Bl2 red cell folate) RCF 66267
Sex hormone binding globulin SHBG 66405
Skeletal muscle—tissue antigens—antibodies SLA 71109
Skin—cytology SMCY 73043
Skin—microscopy and culture of material from MCS2 69207
Skin basement membrane—tissue antigens—antibodies SKA 71109
Snake venom HISS 66231
Smooth muscle—tissue antigens—antibodies SMA 71119
Sodium NA 66201
Solid tissue or tissues—chemical assays ENZS 66285
Solid tissue or tissues—cytology of fine needle aspiration FNCY 73049
Solid tissue or tissues—cytology of fine needle aspiration by, or in presence of, pathologist FNCP 73051
Somatomedin SOMA 66405
Sotalol SALL 66235
Specific IgG or IgE antibodies RAST 71079
Specimen referred fee 73921
Sperm antibodies SAB 73525
Sperm antibodies—penetrating ability SPA 73525
Sputum—cytology (1 specimen) BFCY 73045
Sputum—cytology (3 specimens) SPCY 73047
Sputum—microscopy and culture of specimens MCS2 69207
Sputum—for mycobacteria AFB 69213
Stelazine STEL 66235
Steroid fraction or fractions in urine USF 66405
Streptococcal serology—anti‑DNASE B titre—microbial antibody testing ADNB 69229
Streptococcal serology—anti‑streptolysin O titre—microbial antibody testing ASOT 69229
Streptococcus—Group B STB 69219
Streptococcus pneumoniae—antigens SPN 69219
Streptococcus pneumoniae—microbial antibody testing PCC 69229
Streptococcus pneumoniae—microbial antigen testing SPN 69219
Strontium SR 66277
Sulthiame (Ospolot) SUL 66235
Synacthen stimulation test SYNS 66297
Syphilis serology (see group tests) STS 69231
Testosterone TES 66405
Tetanus—microbial antibody testing TET 69229
Thalassaemia studies TS 65011
Theophylline THEO 66235
Thermoactinomyces vulgaris—microbial antibody testing THE 69229
Thermopolyspora—microbial antibody testing TPS 69229
Thiopentone TOPO 66235
Thioridazine THIO 66235
Throat—microscopy and culture of material from MCS1 69205
Thrombin time TT 65029
Thyroglobulin TGL 66261
Thyroglobulin—tissue antigens—antibodies ATG 71109
Thyroid—function tests TFT 66291
Thyroid-stimulating hormone (where not requested on its own or as part of TFTs) TSH 66371,
66405
Thyroid microsome—tissue antigens—antibodies TMA 71109
Thyrotrophin releasing hormone test TRH 66293
Total free fatty acids TFFA 66367
Total protein PROT 66201
Toxocara—microbial antibody testing TOC 69229
Toxoplasma—microbial antibody testing TOX 69229
TPHA (Treponema pallidum haemagglutination test)—microbial antibody testing TPHA 69229
Treponema pallidum haemagglutination test—microbial antibody testing TPHA 69229
Trichinosis—microbial antibody testing TOS 69229
Triglycerides TRIG 66331
Trimipramine TRIM 66235
Tryptic activity in faeces TAF 66323
TSH receptor antibody test—tissue antigens—antibodies TSHA 71109
TSH (where not requested on its own or as part of a thyroid function test) TSH 66371,
66405
Tuberculosis MANT 73811
Tumour markers—CA‑15.3 antigen CA15 66261
Tumour markers—CA‑19.9 antigen CA19 66261
Tumour markers—CA‑125 antigen C125 66261
Tumour markers—carcinoembryonic antigen CEA 66261
Tumour markers—mammary serum antigen MSA 66261
Tumour markers—mucin‑like carcinoma associated antigen MCA 66261
Tumour markers—neuron specific enolase NSEN 66261
Tumour markers—prostate specific antigen PSA 66357
Tumour markers—prostatic acid phosphatase‑1 or more fractions ACP 66357
Tumour markers—thyroglobulin TGL 66261
Typhus, Weil‑Felix—microbial antibody testing TYP 69229
Urate URAT 66201
Urea U 66201
Urea, electrolytes, creatinine (see group tests in Division A)
Urethra—microscopy and culture of material from MCS2 69207
Urine—bilirubin UBIL 66213
Urine—catalase test 73805
Urine—cytology—on 1 specimen BFCY 73045
Urine—cytology—on 3 specimens SPCY 73047
Urine—cystine (cysteine) UCYS 66213
Urine—haemoglobin UHB 66213
Urine—melanin (melanogen) UML 66213
Urine—microscopy, culture, identification and sensitivity UMCS 69217
Urine—myoglobin UMY 66213
Urine—porphobilinogen UPG 66213
Urine—porphyrins—qualitative test UPR 66213
Urine—steroid fraction or fractions USF 66405
Urine—urobilinogen UUB 66213
Vagina—cytology on specimens from CVO 73057
Vagina—microscopy and culture of material from MCS2 69207
Valproate (Epilim) VALP 66235
Vancomycin VAN 66235
Varicella zoster—microbial antibody testing VCZ 69229
Varicella zoster—microbial antigen testing VCZN 69219
Vasoactive intestinal peptide VIP 66405
Vasopressin ADH 66405
VDRL (Venereal Disease Research Laboratory)—microbial antibody testing VDRL 69229
Viscosity of blood or plasma VISC 65001
Vitamins—B12 RCF 66267
Vitamins—D VITD 66271
Vitamins—folate RCF 66267
Vitamins—quantitation of A, B1, B2, B3, B6, C or E VIT 66269
VMA (see HMMA)
Von Willebrand’s factor VWF 65045
Von Willebrand’s factor antigen VWA 65045
Warfarin WFR 66235
Xylose XYL 66367
Yersinia enterocolitica—microbial antibody testing YER 69229
Zinc ZN 66367
NOTE
1. Notified in the Commonwealth of Australia Gazette on 30 June 1994.
